PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2004 | 3 | 87-100
Article title

New drugs based on recombinant DNA technology

Title variants
Languages of publication
PL
Abstracts
EN
Over the last 20 years, some 100 biopharmaceuticals have gained marketing authorization in Europe, USA and other world regions. All biopharmaceutical products currently approved within the EU are protein-based. The majority of the first generation products were either unmodified monoclonal antibodies or proteins used clinically to either replace or augment levels of native human proteins. With the recent advances in genomics, proteomics, pharmaceutical target validation, and lead compound identification new perspectives of biopharmaceutical products development emerged. Protein engineering has recently facilitated the rational development of a number of proteins displaying an altered pharmacokinetics, biodistribution and therapeutic properties. New strategies and challenges in biopharmaceuticals developments yielded the second generation of protein drugs.
Keywords
Publisher

Journal
Year
Issue
3
Pages
87-100
Physical description
Contributors
References
Document Type
REVIEW
Publication order reference
K. Kiec-Kononowicz, Zaklad Technologii Chemicznej Srodkow Leczniczych Collegium Medicum, Uniwersytet Jagiellonski, ul. Medyczna 9, 30-688 Krakow, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-f6a88777-828b-312a-91c5-50d339aff424
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.